AngioDynamics, Inc. (NASDAQ:ANGO) Q1 2024 Earnings Call Transcript October 4, 2023 AngioDynamics, Inc. beats earnings expectations. Reported EPS is $-0.12, expectations were $-0.14. Operator: Good morning, and welcome to the AngioDynamics Fiscal Year 2024 First Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the […]
Fiscal Year 2024 First Quarter Highlights
Net sales of $78.7 million as reported
Includes $0.7 million of Dialysis and BioSentry Biopsy Tract Sealant System sales
Net sales increased 5.7%.
AngioDynamics Inc (NASDAQ: ANGO) has reported a Q1 FY24 adjusted EPS loss of $(0.12), beating the consensus of $(0.13) but higher than $(0.06) reported a year ago.
H.C. Wainwright initiated coverage on AngioDynamics Inc (NASDAQ: ANGO), noting that the company is debt-free and significantly undervalued compared to peers in a growing market.